[go: up one dir, main page]

SE0004056D0 - N-type calcium channel antagonists for the treatment of pain - Google Patents

N-type calcium channel antagonists for the treatment of pain

Info

Publication number
SE0004056D0
SE0004056D0 SE0004056A SE0004056A SE0004056D0 SE 0004056 D0 SE0004056 D0 SE 0004056D0 SE 0004056 A SE0004056 A SE 0004056A SE 0004056 A SE0004056 A SE 0004056A SE 0004056 D0 SE0004056 D0 SE 0004056D0
Authority
SE
Sweden
Prior art keywords
pain
treatment
type calcium
calcium channel
channel antagonists
Prior art date
Application number
SE0004056A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0004056A priority Critical patent/SE0004056D0/sv
Publication of SE0004056D0 publication Critical patent/SE0004056D0/sv
Priority to US10/415,783 priority patent/US6841680B2/en
Priority to AU2002212897A priority patent/AU2002212897A1/en
Priority to ES01981242T priority patent/ES2319259T3/es
Priority to JP2002539329A priority patent/JP2004513118A/ja
Priority to EP01981242A priority patent/EP1339690B1/en
Priority to PCT/SE2001/002391 priority patent/WO2002036569A1/en
Priority to AT01981242T priority patent/ATE421502T1/de
Priority to DE60137534T priority patent/DE60137534D1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0004056A 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain SE0004056D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0004056A SE0004056D0 (sv) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain
US10/415,783 US6841680B2 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain
AU2002212897A AU2002212897A1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain
ES01981242T ES2319259T3 (es) 2000-11-06 2001-10-31 Antagonistas de canales calcicos de tipo n para el tratamiento del dolor.
JP2002539329A JP2004513118A (ja) 2000-11-06 2001-10-31 疼痛治療のためのn−型カルシウムチャンネル拮抗薬
EP01981242A EP1339690B1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain
PCT/SE2001/002391 WO2002036569A1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain
AT01981242T ATE421502T1 (de) 2000-11-06 2001-10-31 Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
DE60137534T DE60137534D1 (de) 2000-11-06 2001-10-31 Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004056A SE0004056D0 (sv) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
SE0004056D0 true SE0004056D0 (sv) 2000-11-06

Family

ID=20281716

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0004056A SE0004056D0 (sv) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain

Country Status (9)

Country Link
US (1) US6841680B2 (sv)
EP (1) EP1339690B1 (sv)
JP (1) JP2004513118A (sv)
AT (1) ATE421502T1 (sv)
AU (1) AU2002212897A1 (sv)
DE (1) DE60137534D1 (sv)
ES (1) ES2319259T3 (sv)
SE (1) SE0004056D0 (sv)
WO (1) WO2002036569A1 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862301B1 (fr) * 2003-11-17 2007-12-21 Aventis Pharma Sa Nouveau procede de preparation de quinoleines 3-fluorees
EP1871372A4 (en) * 2005-04-08 2010-06-02 Neuromed Pharmaceuticals Ltd COMBINATION THERAPY WHICH INCLUDES AN AGENT BLOCKING CALCIUM CHANNELS OF TYPE N FOR THE RELIEF OF PAIN
EP2019676A2 (en) * 2006-05-11 2009-02-04 Neuromed Pharmaceuticals, Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
PT2634177T (pt) * 2010-10-29 2016-08-18 Clino Ltd Sonda de imagem de tau
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
JP2014507424A (ja) 2011-03-08 2014-03-27 ザリカス ファーマスーティカルズ リミテッド 固体分散物製剤およびその使用方法
DE102016125645A1 (de) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2114727C (en) * 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants

Also Published As

Publication number Publication date
EP1339690A1 (en) 2003-09-03
US6841680B2 (en) 2005-01-11
ES2319259T3 (es) 2009-05-06
DE60137534D1 (de) 2009-03-12
ATE421502T1 (de) 2009-02-15
AU2002212897A1 (en) 2002-05-15
EP1339690B1 (en) 2009-01-21
US20040053965A1 (en) 2004-03-18
JP2004513118A (ja) 2004-04-30
WO2002036569A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
ATE302770T1 (de) Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
ATE376996T1 (de) Antibakterielle mittel
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
ATE284392T1 (de) Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
EP1233956A4 (en) BRYOSTATIN ANALOGUES, METHODS OF SYNTHESIS AND USES
BE2011C037I2 (sv)
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
DE60107941D1 (de) Blockcopolymerkautschuk, harzmodifizierer und harzzusammensetzung
EP0657942A3 (en) Lateral bipolar transistor.
TR200102178T2 (tr) CRF reseptör antagonistleri ve bunlarla ilgili yöntemler.
SE0102858D0 (sv) N-type calcium channel antagonists for the treatment of pain
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
SE0004056D0 (sv) N-type calcium channel antagonists for the treatment of pain
DE69727711D1 (de) N-alkyl-ammonium-acetonitril-salze, methoden dazu und zusammensetzungen die diese enthalten
DE60139195D1 (de) Aktivierbare polymerzusammensetzung, und gegenstände, die diese nutzen
NO20030868D0 (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
DE69735479D1 (de) Metalloproteinase inhibitoren
NO20054668L (no) Aplidin for multippelt myelom-behandling
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
SE0004055D0 (sv) N-type calcium channel antagonists for the treatment of pain
DE60129123D1 (de) BIOLOGISCH AKTIVE 4H-BENZOi1,4öOXAZIN-3-ONE
AU2002210491A1 (en) Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva